2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. ELOVL

ELOVL

Elongation of Very Long-chain Fatty Acids; Elongase

ELOVL (Elongation of Very Long-chain Fatty Acids; Elongase) is a cyclic rate-limiting enzyme that catalyzes the elongation of aliphatic carbon chains, adding carbon units to form polyunsaturated fatty acids. ELOVL is associated with a variety of diseases and has seven isoforms (ELOVL1-7) in mammals, each with its own substrate preference and tissue distribution specificity. ELOVL inhibitors can inhibit ELOVL enzyme activity and block VLCFA elongation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12146
    ELOVL6-IN-2
    		99.91%
    ELOVL6-IN-2 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-2 inhibits mouse ELOVL6 activities, with an IC50 value of 34 nM.
    ELOVL6-IN-2
  • HY-152947
    ELOVL6-IN-4
    		98.04%
    ELOVL6-IN-4 is a potent, selective, and orally active long chain fatty acid elongase 6 (ELOVL6) inhibitor with IC50s of 79 nM and 94 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-4 shows excellent selectivity over the other human ELOVL subtypes (ELOVL1, -2, -3, and -5) and mouse ELOVL3.
    ELOVL6-IN-4
  • HY-145272
    ELOVL1-IN-3
    		99.81%
    ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)[1].
    ELOVL1-IN-3
  • HY-145122
    ELOVL1-IN-1
    		98.02%
    ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD).
    ELOVL1-IN-1
  • HY-145270
    ELOVL1-IN-2
    		99.82%
    ELOVL1-IN-2 is an elongation of very long chain fatty acid 1 (ELOVL1) enzyme inhibitor, ELOVL1-IN-2 shows weak ELOVL1 inhibition (IC50=21 μM) and moderate potency in a primary cellular assay (HEK293 C26 IC50=6.7 μM) .
    ELOVL1-IN-2
  • HY-NP0204
    Mouse Serum Albumin
    		Activator
    Mouse Serum Albumin is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
    Mouse Serum Albumin
  • HY-139451
    ELOVL6-IN-3
    		99.19%
    ELOVL6-IN-1 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-1 dose-dependently inhibits mouse ELOVL6 activities, with an IC50 value of 0.350 μM. ELOVL6-IN-1 inhibits ELOVL6 in a noncompetitive manner for malonyl-CoA (Ki=994 nM) and palmitoyl-CoA.
    ELOVL6-IN-3
  • HY-160912
    ELOVL6-IN-5
    		Inhibitor
    ELOVL6-IN-5 (compound B) is an inhibitor of the elongase enzyme of long-chain fatty acid family 6 (ELOVL6). ELOVL6 is a rate-limiting enzyme for the elongation of saturated and monounsaturated long-chain fatty acids and is an effective target for inhibiting diabetes. ELOVL6-IN-5 reduces hepatic fatty acid levels in a mouse model of diet-induced obesity (DIO). However, ELOVL6 inhibition by ELOVL6-IN-5 did not improve insulin resistance.
    ELOVL6-IN-5
Cat. No. Product Name / Synonyms Application Reactivity